


BRIEF BIOGRAPHY



Norman M. Kaplan, MD
The University of Texas Southwestern Medical Center
5323 Harry Hines Blvd
Dallas, Texas 75390-8899

Phone: 214/ 648-2103
FAX: 214/ 648-7979

Dr. Kaplan is Clinical Professor of Internal Medicine at the University of Texas Southwestern Medical Center at Dallas where he has been on the faculty for more than forty years. For the last twenty, his teaching, writing and research have focused primarily upon clinical aspects of hypertension. He has lectured extensively and contributed over 500 papers to the medical literature. The ninth edition of his textbook, *Kaplan's Clinical Hypertension*, was published in 2006. He was a member of the third, fourth, fifth, and sixth Joint National Committees on Detection, Evaluation and Treatment of High Blood Pressure. He has been made a Master of the American College of Physicians, given the Lifetime Achievement Award by the American Heart Association's Council for High Blood Pressure Research, and received the Stevo Julius Award for Leadership in Medical Communication presented by the International Society of Hypertension. He served on the Executive Committees of the American Society of Hypertension and the AHA Council for High Blood Pressure Research. He is involved as either editor or reviewer with most of the journals which publish papers in the hypertension arena.

CURRICULUM VITAE
Norman M. Kaplan, M.D.

MAILING ADDRESS:

The University of Texas Southwestern Medical Center at Dallas
5323 Harry Hines Blvd.
Dallas, TX 75390-8899

DOB: 1/2/31 (Dallas, Texas) **SS #:** 452-40-3980

EDUCATION:

1943-47: Forest Avenue High School, Dallas, Texas
1947-50: The University of Texas; Austin, Texas; B.S. in Pharmacy
1950-54: The University of Texas Southwestern Medical School; Dallas, Texas; M.D.
1954-55: Internship; Parkland Memorial Hospital; Dallas, Texas
1955-58: Residency in Internal Medicine; Parkland Memorial Hospital; Dallas, Texas

POSITIONS:

1958-60: Military Service: Chief, Endocrinology Service, Department of Medicine, USAF Lackland AFB; San Antonio, Texas
1960-61: Research Fellowship; Clinical Endocrinology Branch, National Heart Institute, National Institutes of Health; Bethesda, Maryland
1961-62: Instructor; Department of Internal Medicine; The University of Texas Southwestern Medical School; Dallas, Texas
1962-68: Assistant Professor; Department of Internal Medicine; The University of Texas Southwestern Medical School; Dallas, Texas
1968-70: Associate Professor; Department of Internal Medicine; The University of Texas Southwestern Medical School; Dallas, Texas
1970-75: Professor; Department of Internal Medicine; The University of Texas Southwestern Medical School; Dallas, Texas
1975-76: Deputy Vice President of Research Programs; American Heart Association; Dallas, Texas
1977-2000: Professor; Department of Internal Medicine; The University of Texas Southwestern Medical School; Dallas, Texas
1980-97: Head, Division of Hypertension; Department of Internal Medicine; The University of Texas Southwestern Medical School; Dallas, Texas
2000-Present: Clinical Professor; Department of Internal Medicine; The University of Texas Southwestern Medical School; Dallas, Texas

SPECIAL FELLOWSHIP:

1/70-7/70: Harvard Center for Community Health and Medical Care

CERTIFICATIONS:

American Board of Internal Medicine – 1963 (Diplomate)
Subspecialty: Endocrinology and Metabolism – 1972
American Society of Hypertension Specialist – 1999

SOCIETY MEMBERSHIPS:

American Federation for Clinical Research – 1958
The Endocrine Society – 1960
Central Society for Clinical Research – 1963
Southern Society for Clinical Research – 1963
American College of Physicians, Fellow – 1964; Master – 1997
American Society for Clinical Investigation – 1966
The Council for High Blood Pressure Research – 1969
Executive Committee – 1996-2000
International Society of Hypertension – 1974
American Public Health Association – 1979
Inter-American Society of Hypertension – 1980
Council on Epidemiology, American Heart Association (Fellow) – 1981
American College of Preventive Medicine – 1982
American Society of Hypertension – 1985
Executive Committee – 1990-2000
Secretary – 1996-98
Member, ASH Specialists Program 1999-
Chairman, ASH Specialist Program 2005-

AWARDS: Lifetime Achievement Award, The Council for High Blood Pressure Research, 1997
Master, American College of Physicians, 1997
Great Teacher Award, National Institutes of Health, 2001
International Society of Hypertension Stevo Julius Award for Scientific Communication, 2004

EDITORIAL BOARDS:

Journal of Clinical Endocrinology and Metabolism – 1976-80
Seminars in Nephrology – 1980-96
American Heart Journal – 1980-86
American Journal of Nephrology – 1981-93
Journal of Hypertension – 1982-90, 2000-2004
American Journal of Cardiology – 1982- 2006
Center for the Science in the Public Interest Nutrition Action Healthletter – 1985-
Cardiovascular Drugs and Therapy (Associate Editor) – 1986-2000
Medicine International - 1986
American Journal of Hypertension (Associate Editor) – 1987- 2005

Clinical Diabetes – 1987 – 2003
Hypertension – 1988-1993; Associate Editor, 2004
Journal of Human Hypertension – 1988 –
Year Book of Cardiology (Editor, Section on Hypertension) – 1988 – 2005
Drug Investigation – 1989 –
Cardiovascular Pharmacology – 1990 –
Up-to-Date, Nephrology – Editor for Hypertension – 1995 –
Current Hypertension Reports-Co-editor, October issues

REVIEWER: Approximately 25 peer-reviewed journals

RESEARCH GRANTS:

National Institutes of Health Research Grants – 1961-75
National Institutes of Health Preventive Cardiology Academic Award – 1979-84

SPECIAL APPOINTMENTS:

National Heart, Lung, and Blood Institute;
Arteriosclerosis, Hypertension, and Lipid Metabolism
Advisory Committee – 1978; Chairman – 1980
National Conference on High Blood Pressure Control
Chairman – 1980-81
National Academy of Science Committee on Implementation of Dietary
Guidelines, Co-Chairman – 1988
NHLBI Hypertension SCOR Committee
Chairman – 1989-90
Third Joint National Committee on Detection, Evaluation, and Treatment of High
Blood Pressure, Member – 1983-84
Fourth Joint National Committee on Detection, Evaluation, and Treatment of
High Blood Pressure, Member – 1987-88
Fifth Joint National Committee on Detection, Evaluation, and Treatment of High
Blood Pressure, Member – 1992-93
Sixth Joint National Committee on Detection, Evaluation, and Treatment of High
Blood Pressure, Member – 1996-97
World Health Organization/International Society of Hypertension
Guidelines Committee – 2001-2003

COMMITTEE ASSIGNMENTS:

University of Texas Southwestern Medical Center at Dallas
- Continuing Education Committee – 1982-98
- GCRC Executive Committee – 1990-96
- Alumni Association, Board of Directors, President – 1980-82
- Chairman, 50th Medical School Reunion, 2004

EXTERNAL

- National High Blood Pressure Education Committee, NHLBI
1980-82; 1995- 2002
- Inter-Society Commission for Heart Disease Resources – 1983-84

POSTGRADUATE EDUCATIONAL ACTIVITIES (AT UTHSCD):

Attending Physician, Parkland Hospital, 1961-
Updates in Internal Medicine, Director – 1982-98
Parkland Hospital Medicine Housestaff Reunion, Chairman – 1985
MKSAP-VII Review Course, Director – 1986
MKSAP-VIII Review Course, Director – 1988-89

POSTGRADUATE EDUCATIONAL ACTIVITIES (ELSEWHERE):

Delegation Leader

- Professional Seminar Consultants, Soviet-American Hypertension
Clinical Study Group, USSR, October 10-24, 1982
- People to People Citizen Ambassador Program, People's Republic of
China, August, 1985
- Chairman or Participant in Multiple Medical School Grand Rounds,
Resident and Staff Conferences, CME Programs, and
Pharmacological company-sponsored symposia (approximately
20/year for 20 years)

Lecturer:

- Lecturer at over 500 Local, National and International meetings

PUBLIC EDUCATIONAL ACTIVITIES:

Moderator, Here's To Your Health, Produced by KERA-TV for Public Television
– 1984-88

- Nominated for Day-time Emmy Award for Talk/Service Show Host, 1986,
Academy of Television Arts and Sciences

SELECTED PUBLICATIONS:

JOURNAL ARTICLES AND ABSTRACTS (1996-Present, most recent first):

Kaplan NM. The ASCOT trial: A closer look. Hypertension. 2006 Feb 24:211-214.

Kaplan NM. Controversies in hypertension. Lancet. 2006 Jan 14;367(9505):168-76.

Kaplan NM. Treatment of hypertension: remaining issues after the Anglo-Scandinavian Cardiac Outcomes Trial. *Hypertension*. 2006 Jan;47(1):10-3.

Kaplan NM. A conversation with Drs. Kaplan and Moser about conflicting data, confusing results, and some recent treatment recommendations for the management of hypertension. *J Clin Hypertens (Greenwich)*. 2005 Oct;7(10):606-11.

Kaplan NM. Clinical trials report. Good news and bad news: first the good news. *Curr Hypertens Rep*. 2005 Oct;7(5):309.

Kaplan NM. An updated meta-analysis with a few surprises. *Hypertension*. 2005 Aug;46(2):257-8.

Kaplan NM. Resistant hypertension. *J Hypertens*. 2005 Aug;23(8):1441-4.

Kaplan NM. Systemic hypertension: an overview of the problem. *Semin Nephrol*. 2005 Jul;25(4):191-3.

Kaplan NM. Task Force 5: systemic hypertension. *J Am Coll Cardiol*. 2005 Apr 19;45(8):1346-8.

Kaplan NM. Hypertension curriculum review: lifestyle modifications for prevention and treatment of hypertension. *J Clin Hypertens* 2004;6:716-9.

Kaplan NM. The place of diuretics in preventing cardiovascular events. *J Hum Hypertens* 2004;18(Suppl 2):S29-S32.

Kaplan NM. What is the impact of systolic blood pressure lowering on preventing cardiovascular events? *J Hum Hypertens* 2004;18(Suppl 2):S1.

Kaplan NM. Exercise and atherosclerosis [Letter]. *Ann Intern Med* 2004;141:890.

Kaplan NM. The two-edged sword: controlling hypertension without destroying the patient. *Blood Press* 2004;13:212-3.

Kaplan NM. Clinical trials report. Adverse prognostic significance of new diabetes in treated hypertensive subjects. *Curr Hypertens Rep* 2004;6:339-40.

Kaplan NM. Trial of Preventing Hypertension (TROPHY): design and 2-year progress report. *Hypertension* 2004;44:125-6.

Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. *J Hypertens* 2004;22:863-9.

Kaplan NM. Executive summaries on hypertension III. Managing difficult-to-treat hypertension. *Drugs Today (Barc)*. 1998 Feb;34(2):139-43.

Kaplan NM. Executive summaries on hypertension II. Choices of initial drug therapy. *Drugs Today (Barc)*. 1998 Jan;34(1):17-23.

Kaplan NM. What can we expect from new guidelines? *Med Clin NA* 2004;88:141-8.

Kaplan NM. Inappropriate aggression [Letter]. *Lancet* 2004;363:86.

Kaplan NM. The current epidemic of primary aldosteronism: Causes and consequences. *J Hypertens* 2004;22:863-869.

Kaplan NM. What can we expect from new guidelines? *Med Clin NA* 2004;88:141-148.

Kaplan NM. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. *Curr Hypertens Rep*. 2003 Oct;5(5):362-3.

Kaplan NM. Nonpharmacologic treatment of hypertension in primary health care. *Curr Hypertens Rep*. 2003 Oct;5(5):361-2.

Kaplan NM. Morning surge in blood pressure. *Circulation* 2003;107:1347.

Kaplan NM. The meaning of ALLHAT. *J Hypertens* 2003;21:233-234.

Kaplan NM. Suggestions for improving the effectiveness of oral presentations. *J Invest Med* 2002;50:419-420.

Kaplan NM. [The challenge to treat hypertensive patients with type 2 diabetes]. *Presse Med* 2002;31. Spec No 2:S25-6. French.

Kaplan NM. Hypertension and diabetes. *J Hum Hypertens*. 2002;16(Suppl 1):S56-60.

Kaplan NM. Another scare about antihypertensive therapy. *Am J Cardiol* 2001;87:759-60.

Kaplan NM. Caution about the overdiagnosis of primary aldosteronism. *Mayo Clin Proc* 2001; 76:875-76.

Kaplan NM. Cautions over the current epidemic of primary aldosteronism. *Lancet* 2001;357:953-54.

Kaplan NM. Hypertension trials: 1990 to 2000. *Curr Opin Nephrol Hypertens* 2001;10:501-05.

Kaplan NM. Inferiority of calcium channel blockers to cheaper drugs. News item was inaccurate on at least two counts [Letter]. *Br Med J* 2001;322:671-72.

Kaplan NM. Low-dose combination therapy: the rationalization for an ACE inhibitor and a calcium channel blocker in higher risk patients. *Am J Hypertens* 2001;14:8S-11S.

Kaplan NM. Management of hypertensive patients with multiple cardiovascular risk factors. *Am J Hypertens* 2001;14:221S-224S.

Kaplan NM. Management of hypertension in patients with type 2 diabetes mellitus: Guidelines based on current evidence. *Ann Intern Med* 2001;135:1079-83.

Kaplan NM. Should new drugs be used without outcome data? Implications of ALLHAT and Elite II. *Arch Intern Med* 2001;161:511-12.

Kaplan NM. Treatment of coexisting diabetes and hypertension. *Curr Cardiol Rep* 2001;3:498-503.

Kaplan NM. What is goal blood pressure for the treatment of hypertension? *Arch Intern Med* 2001;161:1480-82.

Kaplan NM. A cardioprotective approach to the management of hypertension. *J Hypertens* 2000;18(Suppl):S29-S31.

Kaplan NM. Angiotensin II-receptor blockers: Will they replace angiotensin-converting enzyme inhibitors in the treatment of hypertension? *J Hum Hypertens* 2000;14(Suppl 1):S87-S90.

Kaplan NM. Another scare about antihypertensive therapy. *Lancet* 2000;356:1933.

Kaplan NM. Diuretics as a basis of antihypertensive therapy. An overview. *Drugs* 2000;59(Suppl 2):21-25.

Kaplan NM. Drug treatment: An overview of progress and a look to the future. *J Hum Hypertens* 2000;14:725-27.

Kaplan NM. Evidence in favor of moderate dietary sodium reduction. *Am J Hypertens* 2000;13:8-13.

Kaplan NM. Guidelines for the management of hypertension. *Can J Cardiol* 2000;16:1147-52.

Kaplan NM. Hypertension in the Elderly. *Primary Care Rep* 2000;6:129-38.

Kaplan NM. Maximizing antihypertensive management in the elderly. *Cleveland Clinic J Med* 2000;67:551-53.

Kaplan NM. New issues in the treatment of isolated systolic hypertension. *Circulation* 2000;102:1079-81.

Kaplan NM. The dietary guideline for sodium: Should we shake it up? No. *Am J Clin Nutr* 2000;71:1020-26.

Kaplan NM. Angiotensin II receptor antagonists in the treatment of hypertension. *Am Fam Physician* 1999;60:1185-90.

Kaplan NM. Diuretics: Correct use in hypertension. *Semin Nephrol* 1999;19:569-74.

Kaplan NM. Low-dose combination drugs. A new approach to first-intention treatment of hypertension. *Presse Med* 1999;28:2165-67. French.

Kaplan NM. Low dose combinations in the treatment of hypertension: Theory and practice. *J Hum Hypertens* 1999;13:707-10.

Kaplan NM. Review of hypertension in practice, Third Edition. *J Hum Hypertens* 1999;13:647.

Kaplan NM. Self-reported blood pressure reliability problems exaggerated. *Am J Hypertens* 1999;12:538-39.

Kaplan NM. The importance of moderate sodium reduction in the nonpharmacological therapy of hypertension. *J Clin Hypertens* 1999;1:115-19.

Kaplan NM. The place for beta-blockers in treating hypertension. *Eur Heart J* 1999;20:5-6.

Kaplan NM. Three recently published trials in hypertension. *Curr Hypertens Rep* 1999;1:377-78.

Kaplan NM, Palmer BF, Nassar NN, et al. Southwestern Internal Medicine Conference. Keeping travelers healthy. *Am J Med Sci* 1998;315:327-36.

Kaplan NM. Commentary on the sixth report of the Joint National Committee (JNC-6). *Am J Hypertens* 1998;11:134-36.

Kaplan NM. J-curve not burned off by HOT study. *Lancet* 1998;351:1748-49.

Kaplan NM. JNC VI guidelines. *Lancet* 1998;351:288.

Kaplan NM. New JNC-6 guidelines. Joint National Committee. *Am J Kidney Dis* 1998;31:864-65.

Kaplan NM. Norman Mayer Kaplan, MD: A conversation with the editor. Interview by William C. Roberts. *Am J Cardiol* 1998;82:490-504.

Kaplan NM. Obesity in hypertension: Effects on prognosis and treatment. *J Hypertens* 1998;16(Suppl):S35-S37.

Kaplan NM. The endothelium as prognostic factor and therapeutic target: what criteria should we apply? *J Cardiovasc Pharmacol* 1998;32(Suppl 3):S78-S80.

- Kaplan NM. The sixth joint national committee report (JNC-6): New guidelines for hypertension therapy from the USA. *Keio J Med* 1998;47:99-105.
- Kaplan NM. Treatment of hypertension: Insights from the JNC-VI report. *Am Fam Physician* 1998;58:1323-30.
- Kaplan NM. Ventrolateral medullary decompression in essential hypertension. *Lancet* 1998;352:1549-50.
- Kaplan NM. Anxiety-induced hyperventilation. A common cause of symptoms in patients with hypertension. *Arch Intern Med* 1997;157:945-48.
- Kaplan NM. Beta blockade in the primary prevention of hypertensive cardiovascular events with focus on sudden cardiac death. *Am J Cardiol* 1997;80:20J-22J.
- Kaplan NM. The challenge of managing multiple cardiovascular risk factors. *Am J Hypertens* 1997;10:167S-169S.
- Kaplan NM, Sever PS. Combination therapy: A key to comprehensive patient care. *Am J Hypertens* 1997;10:127S.
- Kaplan NM, Gifford RW Jr. Choice of initial therapy for hypertension. *JAMA* 1996;275:1577-80.
- Kaplan NM. Cost considerations in the drug treatment of hypertension. Is older better? *Pharmacoeconomics* 1996;9:283-85.
- Kaplan NM. Diuretics: Cornerstone of antihypertensive therapy. *Am J Cardiol* 1996;77:3B-5B.
- Kaplan NM. Do calcium antagonists cause cancer? *Lancet* 1996;348:541-42.
- Kaplan NM. Do calcium antagonists cause death, gastrointestinal bleeding, and cancer? *Am J Cardiol* 1996;78:932-33.
- Kaplan NM. Do calcium antagonists cause myocardial infarction? *Am J Cardiol* 1996;77:81-82.
- Kaplan NM. Medicine and the media. *Lancet* 1996;348:270.
- Kaplan NM. Primary hypertension. From pathophysiology to prevention. *Arch Intern Med* 1996;156:1919-20.
- Kaplan NM. The calcium channel blocker controversy. *Hypertens Res* 1996;19:57-64.
- Kaplan NM. The CARE Study: A postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. *Clin Ther* 1996;18:658-70.

Kaplan NM. The costs of antihypertensive therapy. *Arch Intern Med* 1996;156:110-11.

Kaplan NM. The deadly quartet and the insulin resistance syndrome: An historical overview. *Hypertens Res* 1996;19(Suppl 1):S9-S11.

Kaplan SA, Kaplan NM. Alpha-blockade: Monotherapy for hypertension and benign prostatic hyperplasia. *Urology* 1996;48:541-50.

CHAPTERS (1996-Present, most recent first):

Kaplan NM. Hypertension, in *Year Book of Cardiology*, R.C. Schlant, ed. Mosby, St. Louis. 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005.

Kaplan NM, et al. Diuretics and Antihypertensive Drugs, in *Drugs for the Heart*, 2nd, 3rd, 4th, 5th, and 6th eds., L.H. Opie and B.J. Gersh, ed. Elsevier Saunders Co., Philadelphia. 1998-2005.

Kaplan NM. "Systemic Hypertension: Mechanisms and Diagnosis." in *Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine*, 1, 2, 3, 4, 5, 6, and 7 eds. Braunwald E, ed. Philadelphia: Saunders, 1980-2005.

Kaplan NM. "Systemic Hypertension: Therapy." in *Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine*, 1, 2, 3, 4, 5, 6, and 7 eds. Braunwald E, ed. Philadelphia: Saunders, 1980-2005.

Kaplan NM. "Hypertension and Diabetes." Chapter 47 in *Ellenberg & Rifkin's Manual of Diabetes Mellitus*, 3rd ed. 2004.

Kaplan NM. Tailoring Hypertensive Therapy to the Individual Patient. Chapter 25 in *Handbook of Hypertension*, vol 22. *Hypertension in the Twentieth Century: Concepts and Achievements*. WH Birkenhäger and JL Reid, eds. Amsterdam: Elsevier. 2004.

Kaplan NM. Individualization of Pharmacological Therapy. Chapter 57 in *Therapy in Nephrology and Hypertension*, 2nd ed. HR Brady and CS Wilcox, eds. London: WB Saunders. 2003.

Kaplan NM. Refractory Hypertension. Chapter 128 in *Hypertension Primer*, 3rd ed. Izzo and Black, eds. Am Heart Assoc. 2003.

Kaplan NM. Management of Hypertension, in *Atherosclerosis and Coronary Artery Disease*, 2nd ed. V. Fuster, E.J. Topol, and E.G. Nabel, eds. Raven Press. 2003.

Kaplan NM. Strategies for Treatment of Hypertension, in *Lifestyle Modification for the Prevention and Treatment of Hypertension*, P.K. Whelton, J. He, and G.T. Louis, eds. Marcel Decker, Inc. New York. 2003.

Kaplan NM. Hypertension Therapy. in Essential Cardiology: Principles and Practice. C. Rosendorff, ed. Philadelphia: WR Saunders, 2001, 2005.

Kaplan NM. Hypertension, in Cardiovascular Medicine, 2nd ed., JT Willerson and JN Cohn, eds. Livingstone, New York. 2000.

Kaplan NM. Established Hypertension: Initial Therapy, in The ABCs of Antihypertensive Therapy, F.H. Messerli, ed. Authors' Publishing House, New York. 2000.

Kaplan NM. The Adrenal Glands, in Textbook of Endocrine Physiology, 3rd and 4th ed. J.E. Griffin and S.R. Ojeda, eds. Oxford Press, New York. 1996, 2000.

BOOKS (1996-Present, most recent first):

Kaplan NM. Kaplan's Clinical Hypertension, 9th ed. Philadelphia: Lippincott Williams & Wilkins, 2006.

Kaplan NM. Handbook of Hypertension, Vol 22nd. Elsevier, Amsterdam. 2004.

Kaplan NM, Weber MA. Hypertension Essentials, 2003. Physician's Press. Royal Oak, MI. 2003.

Kaplan NM. Systolic Blood Pressure: A Determinant of Comorbidity. Science Press. London. 2003.

Kaplan NM. Hypertension, Microcirculation and End Organ Damage. Lippincott, Williams & Wilkins. Philadelphia. 2002.

Kaplan NM. Management of Hypertension, 8th ed. Castle Connolly Graduate Medical Publishing, New York, NY. 2002.

Kaplan NM. Hypertension in the Elderly, 1st and 2nd ed. Martin Dunitz, London. 1999, 2002.

Kaplan NM, ed. Hypertension Therapy Annual. Martin Dunitz, London. 2000, 2002.

Kaplan NM. Treatment of Hypertension in General Practice. Martin Dunitz, London. 2001.

Kaplan NM. Hypertension and Concomitant Disorders: Role of Alpha-Blockade. Science Press, London. 2001.

Kaplan NM, MacGregor G. Hypertension. Health Press, Oxford. 1998.

Kaplan NM, Kendall M, Horton R. Difficult Hypertension. Martin Dunitz, London. 1996.

ELECTRONIC-BASED PUBLICATIONS:

Kaplan NM. Primary Aldosteronism. Physicians' Information and Education Resource (PIER).
Philadelphia: American College of Physicians. 2001, 2003.